Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-317-7
CAS number: 119-36-8
distribution of salicylate to embryonal tissues was statistically
comparable in vivo and in vitro, although the embryos in vitro
accumulated slightly (but not significantly) less of the chemical. There
was considerable binding of salicylate by maternal serum and culture
medium proteins: less than 20% of the chemical was free at the 40 ug/ml
concentration used in this experiment. Consequently, the salicylate
concentration in embryonal compartments appeared to be quite low when
compared to the surrounding serum/medium, but was actually equal to or
greater than the concentration of unbound salicylate in serum or culture
medium. The proportion of free salicylate in serum increased at
concentrations higher than 40 ug/ml, resulting in somewhat higher
concentrations of salicylate in in vitro embryos and extra-embryonic
fluid (as compared to medium) when cultured in the presence of 200 or
400 ug/ml salicylate.
was significantly more salicylate distributed to gestation day 20.5
fetal tissues than to gestation day 12.5 embryos. This appeared to
result from a higher percentage of unbound salicylate in maternal serum
in late gestation, but may also be due to other factors such as
different placental characteristics or binding within embryo/fetal
compartments. In summary, under the conditions of this study the
disposition of salicylate to embryonal compartments was statistically
comparable in vivo and in vitro. Disposition is influenced considerably
by developmental stage and concentration of salicylate.
distribution of salicylate to embryonal compartments for in situ and in
vitro rat embryos under equivalent exposure conditions, and salicylate
disposition in the in vivo mid-gestation embryo and late gestation
fetus, were compared.
Sprague-Dawley CD rats were exposed to steady-state blood levels of
salicylate by infusing14C-salicylic acid iv for a 24 hour
period from gestation day 11.5 to 12.5. Cultured Sprague-Dawley rat
embryos (in medium consisting of 100% male rat serum) were exposed to
the steady-state14C-salicylate concentration achieved in
maternal serum in vivo for the same 24 hour developmental period. At the
end of the exposure period radioactivity in visceral yolk sac,
extra-embryonic fluid and embryos, and in maternal tissues, was measured.
pharmacokinetics in the fetus were determined by infusing14C-salicylic
acid iv into pregnant rats from gestation day 19.5 to 20.5 and
concentrations in fetuses and dams on gestation day 20.5 were compared
to those from gestation day 12.5 rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Siekdami užtikrinti, kad būtų patogu naudotis mūsų svetaine, jos tinklapiuose naudojame slapukus.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again